JP2008538584A - リポソーム中に捕捉されたドキソルビシンによる進行卵巣癌を処置する方法 - Google Patents
リポソーム中に捕捉されたドキソルビシンによる進行卵巣癌を処置する方法 Download PDFInfo
- Publication number
- JP2008538584A JP2008538584A JP2008507989A JP2008507989A JP2008538584A JP 2008538584 A JP2008538584 A JP 2008538584A JP 2008507989 A JP2008507989 A JP 2008507989A JP 2008507989 A JP2008507989 A JP 2008507989A JP 2008538584 A JP2008538584 A JP 2008538584A
- Authority
- JP
- Japan
- Prior art keywords
- administering
- comprises administering
- patient
- liposome
- ovarian cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 35
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 31
- 239000002502 liposome Substances 0.000 title claims abstract description 20
- 229960004679 doxorubicin Drugs 0.000 title claims abstract description 16
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims description 24
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 230000004044 response Effects 0.000 claims abstract description 20
- 229910052697 platinum Inorganic materials 0.000 claims abstract description 14
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 12
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 12
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 12
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 7
- 230000004083 survival effect Effects 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 abstract description 19
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 abstract description 7
- 206010028980 Neoplasm Diseases 0.000 description 19
- 201000011510 cancer Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 4
- 229940115080 doxil Drugs 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102100023123 Mucin-16 Human genes 0.000 description 3
- 208000007660 Residual Neoplasm Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 206010061819 Disease recurrence Diseases 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 238000011518 platinum-based chemotherapy Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 238000011334 debulking surgery Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011396 initial chemotherapy Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67418805P | 2005-04-21 | 2005-04-21 | |
| PCT/US2006/015528 WO2006116341A1 (en) | 2005-04-21 | 2006-04-20 | Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538584A true JP2008538584A (ja) | 2008-10-30 |
| JP2008538584A5 JP2008538584A5 (enExample) | 2009-05-14 |
Family
ID=36811891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008507989A Withdrawn JP2008538584A (ja) | 2005-04-21 | 2006-04-20 | リポソーム中に捕捉されたドキソルビシンによる進行卵巣癌を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070026060A1 (enExample) |
| EP (1) | EP1874324A1 (enExample) |
| JP (1) | JP2008538584A (enExample) |
| KR (1) | KR20080008367A (enExample) |
| CN (1) | CN101163485A (enExample) |
| AU (1) | AU2006238877A1 (enExample) |
| BR (1) | BRPI0609939A2 (enExample) |
| CA (1) | CA2605669A1 (enExample) |
| IL (1) | IL186699A0 (enExample) |
| MX (1) | MX2007013056A (enExample) |
| WO (1) | WO2006116341A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2609216T3 (en) | 2010-08-24 | 2016-09-12 | Dana Farber Cancer Inst Inc | Methods to predict anti-cancer response |
| EP3693473B1 (en) | 2011-06-17 | 2025-02-19 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| UY34295A (es) * | 2011-09-08 | 2013-04-30 | Servier Lab | Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida |
| BR112014015152A2 (pt) | 2011-12-21 | 2017-07-04 | Myriad Genetics Inc | métodos e materiais para a avaliação da perda de heterozigosidade |
| DK3415915T3 (da) | 2012-02-23 | 2024-11-04 | Childrens Medical Center | Fremgangsmåde til at forudsige respons til PARP-inhibitorer |
| AU2013273466B2 (en) | 2012-06-07 | 2018-11-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
| WO2014160080A1 (en) | 2013-03-14 | 2014-10-02 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
| WO2015086473A1 (en) | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| ES2946251T3 (es) | 2014-08-15 | 2023-07-14 | Myriad Genetics Inc | Métodos y materiales para evaluar la deficiencia de recombinación homóloga |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6923966B2 (en) * | 1999-04-08 | 2005-08-02 | Schering Corporation | Melanoma therapy |
| WO2001032145A1 (en) * | 1999-10-29 | 2001-05-10 | Board Of Regents, The University Of Texas System | Method of cancer treatment |
-
2006
- 2006-04-20 BR BRPI0609939-4A patent/BRPI0609939A2/pt not_active IP Right Cessation
- 2006-04-20 KR KR1020077026950A patent/KR20080008367A/ko not_active Withdrawn
- 2006-04-20 CN CNA2006800130738A patent/CN101163485A/zh active Pending
- 2006-04-20 WO PCT/US2006/015528 patent/WO2006116341A1/en not_active Ceased
- 2006-04-20 MX MX2007013056A patent/MX2007013056A/es not_active Application Discontinuation
- 2006-04-20 AU AU2006238877A patent/AU2006238877A1/en not_active Abandoned
- 2006-04-20 JP JP2008507989A patent/JP2008538584A/ja not_active Withdrawn
- 2006-04-20 CA CA002605669A patent/CA2605669A1/en not_active Abandoned
- 2006-04-20 EP EP06751290A patent/EP1874324A1/en not_active Ceased
- 2006-04-20 US US11/408,201 patent/US20070026060A1/en not_active Abandoned
-
2007
- 2007-10-16 IL IL186699A patent/IL186699A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007013056A (es) | 2008-04-07 |
| CN101163485A (zh) | 2008-04-16 |
| AU2006238877A1 (en) | 2006-11-02 |
| BRPI0609939A2 (pt) | 2010-05-11 |
| WO2006116341A1 (en) | 2006-11-02 |
| CA2605669A1 (en) | 2006-11-02 |
| US20070026060A1 (en) | 2007-02-01 |
| KR20080008367A (ko) | 2008-01-23 |
| EP1874324A1 (en) | 2008-01-09 |
| IL186699A0 (en) | 2008-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Misset et al. | Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer | |
| Fornasiero et al. | Chemotherapy of invasive thymoma. | |
| Cunliffe et al. | Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy | |
| Hainsworth et al. | Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. | |
| Ayash et al. | High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. | |
| Yun et al. | A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer | |
| Mok et al. | Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy | |
| US20070026060A1 (en) | Method for treating advanced ovarian cancer | |
| Taub et al. | Peritoneal mesothelioma | |
| Mori et al. | Neoadjuvant chemotherapy with weekly carboplatin and paclitaxel for locally advanced cervical carcinoma | |
| Laber et al. | A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer | |
| US20020110601A1 (en) | Antineoplastic platinum therapeutic method and composition | |
| US20080213183A1 (en) | Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin | |
| Fujiwara et al. | Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study | |
| Shimonov et al. | Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver | |
| Recchia et al. | A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer | |
| Chao et al. | Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil in locally advanced rectal cancer: pathologic complete response rate and preliminary results of overall and disease-free survival in a single institute in Taiwan | |
| Veronesi et al. | Cis-platinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma | |
| Nagao et al. | Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer | |
| Mougenot et al. | In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer | |
| Rosell et al. | Cyclophosphamide and ifosfamide combination as neoadjuvant chemotherapy for locally advanced nonsmall‐cell lung cancer: A meta‐analytic review | |
| Felip et al. | Preoperative High-Dose Cisplatin Versus Moderate-Dose Cisplatin Combined with Ifosfamide and Mitomycin in Stage IIIA (N2) Non–Small-Cell Lung Cancer: Results of a Randomized Multicenter Trial | |
| Akcali et al. | Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8 | |
| Payne et al. | Upper half body irradiation (UHBI) for extensive small cell carcinoma of the lung | |
| Look et al. | Intraperitoneal 5‐fluorouracil for pseudomyxoma peritoneii |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090324 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090324 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100525 |